Skip Navigation

Cardiovascular Research 2000 47(4):707-714; doi:10.1016/S0008-6363(00)00126-7
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Labinjoh, C.
Right arrow Articles by Webb, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Labinjoh, C.
Right arrow Articles by Webb, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man

Catherine Labinjoha, David E. Newbya,b,*, Pamela Dawsonc, Neil R. Johnstona, Christopher A. Ludlamc, Nicholas A. Boonb and David J. Webba

aClinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, Scotland, UK
bDepartment of Cardiology, Royal Infirmary, Lauriston Place, Edinburgh, EH3 9YW, Scotland, UK
cDepartment of Haematology, Royal Infirmary, Lauriston Place, Edinburgh, EH3 9YW, Scotland, UK

* Corresponding author. Tel. +44-131-536 2749; fax: +44-131-536 2744 d.e.newby{at}ed.ac.uk

Objectives: Angiotensin II and bradykinin are potent endogenous vasoactive peptides which may play a role in the regulation of endogenous fibrinolysis and, thereby, contribute to the beneficial actions of ACE inhibitors. The aims of the study were to determine the acute effect of angiotensin II and bradykinin on the local vascular release of tissue plasminogen activator (t-PA) and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1), and the endothelium-derived haemostatic factor, von Willebrand factor (vWf) from the forearm. Methods: Blood flow, and plasma haemostatic and fibrinolytic factors, were measured in both forearms of sixteen healthy men: eight subjects received intra-arterial angiotensin II (5, 50 and 500 pmol/min) which was coinfused with sodium nitroprusside (SNP; 0.3, 1.5 and 7.5 µg/min, respectively), and eight received intra-arterial bradykinin at 10–3000 pmol/min. Results: Despite substantial rises in plasma angiotensin II concentrations (P<0.001) which caused pressor effects (P<0.003) at the highest dose, angiotensin II infusion did not affect local plasma t-PA, PAI-1 or vWf concentrations. In contrast, bradykinin caused substantial dose-dependent increases in blood flow and t-PA release (>100 ng/100 ml of tissue/min) in the infused forearm (P<0.001 for both) without affecting plasma PAI-1 or vWf concentrations. Conclusions: Despite high local concentrations with breakthrough of significant systemic effects, angiotensin II did not affect acute endothelial cell t-PA, PAI-1 or vWf release in healthy men. In contrast, bradykinin is a potent vasodilator and selective stimulus for acute local t-PA release. This may, at least in part, explain the fibrinolytic actions of ACE inhibitors in heart failure and ischaemic heart disease.

KEYWORDS Thrombolysis; Endothelial Factors; Blood Flow; Angiotensin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
L. J. Murphey, H. A. Malave, J. Petro, I. Biaggioni, D. W. Byrne, D. E. Vaughan, J. M. Luther, M. Pretorius, and N. J. Brown
Bradykinin and Its Metabolite Bradykinin 1-5 Inhibit Thrombin-Induced Platelet Aggregation in Humans
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1287 - 1292.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. J. Oliver, D. J. Webb, and D. E. Newby
Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans
Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2470 - 2479.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Chia, C. A. Ludlam, K. A. A. Fox, and D. E. Newby
Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men
J. Am. Coll. Cardiol., January 15, 2003; 41(2): 333 - 339.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
I. B Wilkinson, J. T Affolter, S. L de Haas, M Paola Pellegrini, J. Boyd, M. J Winter, R. J Balment, and D. J Webb
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man
Cardiovasc Res, February 1, 2002; 53(2): 341 - 347.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. Minai, T. Matsumoto, H. Horie, N. Ohira, H. Takashima, H. Yokohama, and M. Kinoshita
Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors
J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1565 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
L. Dezsi
Fibrinolytic actions of ACE inhibitors: a significant plus beyond antihypertensive therapeutic effects
Cardiovasc Res, September 1, 2000; 47(4): 642 - 644.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.